Smart
Inhalers Market Share, Trends and Growth Analysis by Type (Dry Powder Inhaler
and Metered Dose Inhaler), Application (Asthma, Chronic Obstructive Pulmonary
Disease and others), End User (Hospitals & Clinics, Respiratory Care
Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East
& Africa) - Forecast till 2025
Smart
Inhalers are respiratory inhalers equipped with a digital sensor that tracks
the data, such as the dosage timing, and monitors the use of the inhaler while
scheduling the next dosage as well. It is a new-age digital technology designed
to empower patients, care contributors, researchers, and physicians related to
respiratory diseases through objective and accurate medication monitoring and
reminders. Alerts for the daily dosage are generated via Bluetooth.
According to
Market Research Future (MRFR), the global Smart
Inhaler Market is expected to reach USD 4725.69 MN by 2025. In
its recently published research analysis, MRFR also asserts that the market
would register a whopping CAGR of over 45% throughout the forecast period
(2019-2025). Smart inhalers have been successfully improving patient outcomes
while reducing the significant financial costs associated with suboptimal
medication adherence. This makes smart inhalers the next big thing in the
respiratory care segment.
Increasing
population becoming susceptible to indoor air pollutants worldwide and rise in
the prevalence of asthma & COPD are key factors driving the smart inhalers
market. Moreover, improved adherence rate driven by increasing patient’s
preference to use digitalized medical devices for monitoring daily medication
doses fosters the growth of the market.
Also,
increased collaboration deeds between pharmaceutical companies and smart
inhaler manufacturers to promote technological advancements are contributing to
market growth. Increased focus on advancement in treatment methods,
technological advancements led by R&D programs, online marketing strategies
incorporated by key players in pharmaceutical and biotechnological industries
are some of the major trends observed in the market.
On the other
hand, high costs associated with the smart inhalers and COPD & asthma
treatments, limited availability of smart inhalers, and misinterpretation of
information are some of the major factors obstructing the growth of the market.
Key pharmaceutical companies are adopting digital technology for improved
disease management for asthma and COPD and for improved effectivity of
medicines. Wide range of benefits, including reducing financial costs
associated with suboptimal medication adherence to enhanced efficacy of
medicines, makes smart inhalers most preferred and popular in the respiratory
care segment.
Global Smart
Inhalers Market – Segments
The report is
segmented into four key market dynamics to widen the scope of understanding,
By Type : Dry
Powder Inhaler and Metered-dose Inhaler.
By Application : Asthma and Chronic Obstructive Pulmonary Disease (COPD), among
others.
By End-user : Hospitals & Clinics, Research Institute, and Respiratory
Care Centers, among others.
By Regions : Asia Pacific, North America, Europe, and the
Rest-of-the-World.
Browse Complete
Report : https://www.marketresearchfuture.com/reports/smart-inhalers-market-2117
Global Smart
Inhalers Market – Regional Analysis
North America leads
the global smart inhalers market, accounting for the largest market share.
Increased awareness about asthma and COPD treatment and the increased
adoption of smart inhalers help the region to cut the largest revenue share,
globally. Moreover, large asthma and COPD patient population in the region
foster the regional market growth.
The smart inhalers
market in the European region took the second-largest position holding 31.89%
market share, in 2018. The presence of a number of noteworthy
players such as Novartis, AstraZeneca, and Boehringer Ingelheim drive the
regional market growth. Moreover, the high adoption of smart inhalers in
hospitals and patients in European countries is expected to boost the growth in
the regional market throughout the assessment period.
The Asia pacific
smart inhalers market is emerging as a promising market, globally. Factors,
such as the spreading awareness about the benefits that smart inhalers can
provide in managing asthma and COPD, influence the market growth in the region.
Besides, improvement in healthcare infrastructure with an increased budget for
healthcare expenses would fuel the APAC smart inhalers market. The region is
expected to grow rapidly throughout the forecast duration, with China being the
major revenue contributor.
Global Smart
Inhalers Market – Competitive Analysis
Highly competitive by
nature, the smart inhalers market appears to be fragmented due to the presence
of market titans in the market. To maintain their market positions. Key
companies are venturing into new regions and countries with rapid expansion
plans. Top players are substantially investing in R&D and clinical
trials to accelerate product development and innovations and to cut down
production costs.
Major Players:
Players leading the
global smart inhalers market include AstraZeneca (UK), Adherium (New
Zealand), Cohero Health (US), Gecko Health Innovations, Inc
(US), GlaxoSmithKline (UK), Propeller Health (US), and
Inspiro Medical (Israel), among others.
Industry/Innovation/ Related News:
March 29, 2019 --- Teva Pharmaceuticals
(Israel), a leading pharma company, announced its plans to underpin its smart
inhaler, clinical trial innovations through big data emphasis At MEDinIsrael
conference 2019. At the event, the growing role of technology, big data, and
analytics in the company was discussed alongside, the work the top Israeli pharma
company has been doing in digital health.
The discussion
included the company’s recently FDA-cleared smart inhaler ProAir Digihaler.
Teva is planning to take the data from the smart inhaler about time, and number
of inhalations, flow rate, volume to build an algorithm that can predict asthma
exacerbation. The predicted exacerbation, about five or six days before it hits
shows that it’s possible to prescribe some drugs and avoid the exacerbation.
No comments:
Post a Comment